Download Medical Notes on EvaluatePharma Orphan Drug Report 2020

EvaluatePharma Orphan Drug Report 2020 Medical Notes

About This Presentation

Description:Ever wondered what will the orphan drug landscape look like in the year 2024? Big pharma's recent dominance of the orphan market has invited calls to amend the orphan drug act in the United States. Regardless, orphan drug sales are expected to increase from $119bn in 2018 to $217bn in 2024. Download and check this EvaluatePharma Orphan Drug Report 2020 to learn which company would lead with a 7.6% share of the total orphan market in 2024, which orphan drug would fetch $10bn in 2024, alone and what percentage of worldwide sales will pipeline orphan drugs make up in 2024.

Tags:Orphan drug, pharma, pharmaceutical, drug sales, EvaluatePharma

Published on: Jun 29, 2020 | Views : 1040 | Downloads : 1

Comment

Transcript

No transcript available for this presentation

User Presentation
Related Presentations

United Nations Office on Drugs and Crime (UNODC) World Drug Report 2019 - Booklet 2

About : An experienced pharma professional managing sales, marketing and brand management of top global pharma products Presently leading a team of experts in the development and execution of pharma eCommerce strategies that support GSK products to HCP customers.
Occupation : Medical Professional
Specialty : Other Health Professionals
Country : United States of America
Website :

United Nations Office on Drugs and Crime (UNODC) World Drug Report 2019 - Booklet 2

EvaluatePharma pharmaceutical industry world review 2019 and outlook 2024

United Nations Office on Drugs and Crime (UNODC) World Drug Report 2020 - Booklet 4.3

Rare Diseases and the Orphan Drug Act in the US

Engaging HCPs in Post-Covid-19 Era - Pre-defined Priorities for Pharma Affiliates

COVID-19 immunology research

Pharma 2020 Marketing the future - a paper on the future of the pharmaceutical industry

Pharmacy Handbook to Compliance

Indian API (Active Pharmaceutical Ingredient) Industry - Reaching The Full Potential

Emerging Biopharma’s Contribution to Innovation

HEALTH A TO Z